Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sunitinib in Type B3 Thymoma or Thymic Carcinoma (STYLE)
NCT03449173Phase 2Unknown
- Sponsor
- Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano
- Start
- Mar 2017
- Primary completion
- May 2022
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sunitinib in Thymoma type B3 (B3) and thymic carcinoma (TC), sponsored by Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano. Primary endpoint: Activity of Sunitinib at 4 years. Status: unknown.
02
Drugs
sunitinib
03
Conditions
Thymoma type B3 (B3)thymic carcinoma (TC)
Beyond the preview
Go deeper on NCT03449173.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03449173.